MOLECULAR GENETIC CHANGES AS A MARKER FOR THE EFFICIENCY OF TREATMENT FOR GASTRIC CANCER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The use of molecular genetic markers associated with the course and prognosis of the disease, a response to performed therapy, and the risk of side effects will assist in elaborating an individualized approach to treating patients with gastric cancer.

Full Text

Restricted Access

About the authors

A. Chernousov

I.M. Sechenov First Moscow State Medical University

Email: vichy@list.ru

M. Nemtsova

Research Center of Medical Genetics, Russian Academy of Medical Sciences, Moscow

Email: vichy@list.ru

T. Khorobrykh

I.M. Sechenov First Moscow State Medical University

Email: vichy@list.ru

A. Udilova

I.M. Sechenov First Moscow State Medical University

Email: vichy@list.ru

D. Vychuzhanin

I.M. Sechenov First Moscow State Medical University

Email: vichy@list.ru

R. Nurutdinov

I.M. Sechenov First Moscow State Medical University

Email: vichy@list.ru

References

  1. Скоропад В.Ю. Рациональная тактика лечения местно-распространенного рака желудка: место лучевой терапии // Практ. онкол. - 2009; 1: 28-35.
  2. Whiting J., Sigurdsson A., Rowlands D. еt al. The long term results of endoscopic surveillance of premalignant gastric lesions // Gut. - 2002; 50: 378-81.
  3. Yoshino K., Hirakava K., Nakajima T. еt al. Meeting report of the 74th Congress of the Japanese Gastric Cancer Association // Gastric. Cancer. - 2002; 5: 185-93.
  4. Hamilton S., Altonen L. World Health Organization classification of tumours. Pathology an genetics of tumours of the digestive system / Lyon, 2005; p. 314.
  5. Пальцев М.А., Залетаев Д.В. Системы генетических и эпигенетических маркеров в диагностике онкологических заболеваний / М.: ОАО «Издательство «Медицина», 2009; 384 с.
  6. Japanese Classification of Gastric Cancer. 2nd English Edition. JGCA // Gastric. Cancer. - 1998; 1 (1): 10-24.
  7. Japanese Research Society for Gastric Cancer. The General Rules for the Gastric Cancer Study in Surgery and Pathology // Jpn. J. Surg. - 1981; 11 (2): 127-39.
  8. Sawai K., Takahashi T., Suzuki H. New trends in surgery for gastric cancer in Japan // J. Surg. Oncol. - 1994; 56: 221-6.
  9. Maruyama K., Sasako M., Kinoshita T. et al. Can sentinel node biopsy indicate rational extent of lymphadenectomy in gastric cancer surgery? Fundamental and new information on lymph node dissection // Langenbeck’s Arch. Surg. - 1999; 384: 149-57.
  10. Shimoyama S. Current treatment Strategies for Early Gastric Cancer. The Diversity of Gastric Carcinoma. 2005; 253-70.
  11. Cuschieri A., Weeden S., Fielding J. et al. Patient survival after D1 and D2 resection for gastric cancer: long-term results of the MRC randomized surgical trial. // Br. J. Cancer. - 1999; 79: 1522-30.
  12. Bonenkamp J., Hermans J., Sasako M. et al. Extended lymph node dissection for gastric cancer // N. Engl. J. Med. - 1999; 340: 908-14.
  13. Kurita A., Takashima S., Takayama T. et al. Intraperitoneal chemotherapy for gastric carcinoma combined with peritoneal dissemination by intraperitoneal catheter with a subcutaneous reservoir // Jpn. J. Cancer Chemother. - 1994; 21 (14): 2439-44.
  14. Kang Y., Choi D., Im Y. et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer // Proc. ASCO. - 1996; 15: 215.
  15. Неред С.Н., Клименков А.А., Стилиди И.С. и др. Хирургическое и комбинированное лечение больных раком желудка с высоким риском имплантационного метастазирования // Вопр. онкол. - 2005; 1: 75-80.
  16. Yonemura Y. A new treatment strategy for peritoneal dissemination -peritonectomy intraoperative chemohyperthermia and EPIC. 4th International gastric cancer congress. New York, 2001 April 29-May 2; p. 335.
  17. Fujimoto S., Takahashi M., Mutou T. et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma // Cancer. - 1999; 85: 529-34.
  18. Hirose K., Katayama K., Iida A. et al. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. // Oncology. - 1999; 57: 106-14.
  19. Li Q., Ito K., Sakakura C. et al. Causal relationship between the loss of RUNX3 expression and gastric cancer // Cell. - 2002; 109: 113-24.
  20. Hong S., Jeon E., Oh J. et al. The gene-reduction effect of chromosomal losses detected in gastric cancers // BMC Gastroenterology. - 2010; 10: 138.
  21. Ottini L., Falchetti M., Lupi R. et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives // Ann. Oncol. - 2006; 17 (7): 97-102.
  22. Yashiro M., Inoue T., Nishioka N. Allelic Imbalance at p53 Microsatellite Instability Are Predictive Markers for Resistance to Chemotherapy in Gastric Carcimoma // Ann. Surg. Oncol. - 2009; 16 (10): 2926-35.
  23. Grundei T., Vogelsang H., Ott K. et al. Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma // Clin. Cancer Res. - 2000; 6: 4782-8.
  24. Ott K., Vogelsang H., Mueller J. et al. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma // Clin. Cancer Res. - 2003; 9 (6): 2307-15.
  25. Иванов В.И., Киселев Л.Л. Геномика в медицине / М.: Академкнига, 2005.
  26. Kristensen M., Pedersen P., Melsen G. et al. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients // J. Int. Med. Res. - 2010; 38 (3): 870-83.
  27. Ishida Y., Kawakami K., Tanaka Y. et al. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer // Anticancer Res. - 2002; 22: 2805-9.
  28. Jackman A., Calvert A. Folate-based thymidylate synthase inhibitors as anticancer drugs // Ann. Oncol. - 1995; 6 (9): 871-81.
  29. Zhang Q., Zhao Y., Liao Q. et al. Associations between gene polymorphisms of thymidylate synthase with its protein expression and chemosensitivity to 5-fluorouracil in pancreatic carcinoma cells // Chin. Med. J. (Engl.). - 2011; 124 (2): 262-7.
  30. Баранов В.С., Баранова Е.В., Иващенко Т.Э. и др. Геном человека и гены «предрасположенности». Введение в предиктивную медицину / СПб, 2000; 55 с.
  31. Блохина Е.Б. Роль полиморфизма ферментов цикла фолиевой кислоты (MTHFR, TS) в развитии острого лимфобластного лейкоза // Педиатрия. -2004; 12: 69-71.
  32. Farina-Sarasqueta A., Gosens M., Moerland E. et al. TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients // Anal. Cell. Pathol. (Amst.). - 2010; 33 (1): 1-11.
  33. Ulrich C., Bigler J., Velicer C. et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene // Cancer Epidemiol. Biomarkers Prev. - 2000; 9: 1381-5.
  34. Mandola M., Stoehlmacher J., Zhang W. et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels // Pharmacogenetics. - 2004; 14: 319-27.
  35. Xu Y., Yao L., Ouyang T. et al. P53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer // Clin. Cancer Res. - 2005; 11: 7328-33.
  36. Toyama T., Zhang Z., Nishio M. et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients // Breast Cancer Res. - 2007; 9: R34.
  37. Wu X., Zhao H., Amos C. et al. P53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity // J. Natl. Cancer Inst. - 2002; 94: 681-90.
  38. Sayhan N., Yazici H., Budak M. et al. P53 codon 72 genotypes in colon cancer. / Association with human papillomavirus infection // Res. Commun. Mol. Pathol. Pharmacol. - 2001; 109: 25-34.
  39. Buyru N., Altinisik J., Demokan S. et al. P53 genotypes and haplotypes associated with risk of breast cancer // Cancer Detect. Prev. - 2007; 31: 207-13.
  40. Lancaster J., Brownlee H., Wiseman R. et al. P53 polymorphism in ovarian and bladder cancer // Lancet. - 1995; 346: 182.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies